{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:04:23Z","timestamp":1791180263550,"version":"4.1.0"},"reference-count":89,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over the past 10 years, significant progress has been made in understanding HIV-associated lymphomas and improving the prognosis of these diseases. With the advent of combination antiretroviral therapy and the development of novel therapeutic strategies, most patients with HIV-associated lymphomas are cured. The outcome for the majority of patients with HIV-associated diffuse large B-cell lymphoma and Burkitt lymphoma in particular, is excellent, with recent studies supporting the role of rituximab in these diseases. Indeed, in the combination antiretroviral therapy era, the curability of many patients with HIV-associated lymphoma is similar to their HIV-negative counterparts. New treatment frontiers need to focus on improving the outcome for patients with advanced immune suppression and for those with adverse tumor biology, such as the activated B-cell type of diffuse large B-cell lymphoma and the virally driven lymphomas. Future clinical trials need to investigate novel targeted agents alone and in combination with chemotherapy.<\/jats:p>","DOI":"10.1182\/blood-2011-08-373738","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T03:16:08Z","timestamp":1329362168000},"page":"3245-3255","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":136,"title":["How I treat HIV-associated lymphoma"],"prefix":"10.1182","volume":"119","author":[{"given":"Kieron","family":"Dunleavy","sequence":"first","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8745","key":"2019111811515797800_B1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0140-6736(91)92513-2","article-title":"AIDS-associated non-Hodgkin lymphoma.","volume":"337","author":"Beral","year":"1991","journal-title":"Lancet"},{"key":"2019111811515797800_B2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"8","key":"2019111811515797800_B3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.V98.8.2339","article-title":"Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.","volume":"98","author":"Besson","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111811515797800_B4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11908-003-0055-1","article-title":"Update on the pathogenesis, diagnosis, and therapy of AIDS-related lymphoma.","volume":"5","author":"Little","year":"2003","journal-title":"Curr Infect Dis Rep"},{"issue":"5","key":"2019111811515797800_B5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2005.05613.x","article-title":"AIDS-related lymphomas: from pathogenesis to pathology.","volume":"130","author":"Carbone","year":"2005","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111811515797800_B6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/ajcp\/101.6.773","article-title":"Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas: correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors.","volume":"101","author":"Raphael","year":"1994","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2019111811515797800_B7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2009.25.1322","article-title":"Circulating serum free light chains as predictive markers of AIDS-related lymphoma.","volume":"28","author":"Landgren","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111811515797800_B8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","article-title":"Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.","volume":"88","author":"Nador","year":"1996","journal-title":"Blood"},{"issue":"12","key":"2019111811515797800_B9","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1200\/JCO.1998.16.12.3788","article-title":"Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.","volume":"16","author":"Davi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111811515797800_B10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0959-8049(01)00123-X","article-title":"Epstein-Barr virus associated lymphoproliferations in the AIDS setting.","volume":"37","author":"Ambinder","year":"2001","journal-title":"Eur J Cancer"},{"issue":"9","key":"2019111811515797800_B11","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.1993.11.9.1674","article-title":"Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression.","volume":"11","author":"Carbone","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111811515797800_B12","first-page":"431","article-title":"The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.","volume":"27","author":"Gaidano","year":"2000","journal-title":"Semin Oncol"},{"issue":"7","key":"2019111811515797800_B13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0092-8674(91)90007-L","article-title":"Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.","volume":"65","author":"Henderson","year":"1991","journal-title":"Cell"},{"issue":"5229","key":"2019111811515797800_B14","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1126\/science.7544915","article-title":"TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.","volume":"269","author":"Rothe","year":"1995","journal-title":"Science"},{"issue":"1","key":"2019111811515797800_B15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1470-2045(03)00957-4","article-title":"Emerging pathways in the development of AIDS-related lymphomas.","volume":"4","author":"Carbone","year":"2003","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111811515797800_B16","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma.","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111811515797800_B17","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111811515797800_B18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F","article-title":"Genetic characterization of HHV-8\/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis.","volume":"24","author":"Gaidano","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"2019111811515797800_B19","first-page":"3755","article-title":"Frequent mutation of the 5\u2032 noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.","volume":"89","author":"Gaidano","year":"1997","journal-title":"Blood"},{"issue":"2","key":"2019111811515797800_B20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V84.2.397.397","article-title":"Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype.","volume":"84","author":"Gaidano","year":"1994","journal-title":"Blood"},{"issue":"15","key":"2019111811515797800_B21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas.","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"issue":"6769","key":"2019111811515797800_B22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"2019111811515797800_B23","first-page":"257","article-title":"Molecular pathogenesis of B cell malignancy: the role of BCL-6.","volume":"246","author":"Dalla-Favera","year":"1999","journal-title":"Curr Top Microbiol Immunol"},{"issue":"12","key":"2019111811515797800_B24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1093\/nar\/23.12.2127","article-title":"Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE).","volume":"23","author":"Matsuyama","year":"1995","journal-title":"Nucleic Acids Res"},{"issue":"5299","key":"2019111811515797800_B25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.275.5299.540","article-title":"Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function.","volume":"275","author":"Mittrucker","year":"1997","journal-title":"Science"},{"issue":"5","key":"2019111811515797800_B26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0952-7915(98)80223-9","article-title":"Inhibition of fas death signals by FLIPs.","volume":"10","author":"Tschopp","year":"1998","journal-title":"Curr Opin Immunol"},{"issue":"36","key":"2019111811515797800_B27","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111811515797800_B28","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood-2007-01-069575","article-title":"BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.","volume":"110","author":"Parekh","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111811515797800_B29","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"5870","key":"2019111811515797800_B30","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"7089","key":"2019111811515797800_B31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer.","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"issue":"2","key":"2019111811515797800_B32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1128\/JVI.79.2.1244-1251.2005","article-title":"Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.","volume":"79","author":"Fan","year":"2005","journal-title":"J Virol"},{"issue":"10","key":"2019111811515797800_B33","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2002-10-3090","article-title":"Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts.","volume":"101","author":"Klein","year":"2003","journal-title":"Blood"},{"key":"2019111811515797800_B34","first-page":"S8","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: a progress report.","volume":"111","author":"Jaffe","year":"1999","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2019111811515797800_B35","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2019111811515797800_B36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":"Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.","volume":"18","author":"Vega","year":"2005","journal-title":"Mod Pathol"},{"issue":"12","key":"2019111811515797800_B37","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111811515797800_B38","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2019111811515797800_B39","first-page":"15","article-title":"Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome: the French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors.","volume":"115","author":"Raphael","year":"1991","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2019111811515797800_B40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/PNVQ0PQGXHVY6L7G","article-title":"HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.","volume":"121","author":"Thompson","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"2019111811515797800_B41","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS.","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111811515797800_B42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2019111811515797800_B43","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2019111811515797800_B44","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111811515797800_B45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111811515797800_B46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2019111811515797800_B47","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"2019111811515797800_B48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/10428194.2010.500051","article-title":"The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.","volume":"51","author":"Dunleavy","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111811515797800_B49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.","volume":"140","author":"Ribera","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111811515797800_B50","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2019111811515797800_B51","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"issue":"30","key":"2019111811515797800_B52","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","article-title":"Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.","volume":"27","author":"Chadburn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111811515797800_B53","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1200\/JCO.2009.27.7087","article-title":"Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma.","volume":"28","author":"Dunleavy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111811515797800_B54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.1989.03420050069041","article-title":"AIDS-associated non-Hodgkin's lymphoma in San Francisco.","volume":"261","author":"Kaplan","year":"1989","journal-title":"JAMA"},{"issue":"23","key":"2019111811515797800_B55","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199706053362304","article-title":"Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.","volume":"336","author":"Kaplan","year":"1997","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111811515797800_B56","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111811515797800_B57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/canjclin.55.4.229","article-title":"Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.","volume":"55","author":"Lim","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2019111811515797800_B58","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","article-title":"AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.","volume":"107","author":"Mounier","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111811515797800_B59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111811515797800_B60","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111811515797800_B61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1097-0142(20010701)92:1<200::AID-CNCR1310>3.0.CO;2-A","article-title":"Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients.","volume":"92","author":"Spina","year":"2001","journal-title":"Cancer"},{"issue":"7","key":"2019111811515797800_B62","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1182\/blood-2005-09-3885","article-title":"The case for rituximab in AIDS-related lymphoma.","volume":"107","author":"Dunleavy","year":"2006","journal-title":"Blood"},{"issue":"25","key":"2019111811515797800_B63","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111811515797800_B64","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","article-title":"Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.","volume":"19","author":"Ratner","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111811515797800_B65","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2249.1998.00640.x","article-title":"Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis.","volume":"113","author":"Johnson","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"2019111811515797800_B66","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/088922200308972","article-title":"Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.","volume":"16","author":"Phenix","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"2019111811515797800_B67","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","article-title":"Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).","volume":"22","author":"Sparano","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111811515797800_B68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B","article-title":"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.","volume":"91","author":"Vaccher","year":"2001","journal-title":"Cancer"},{"issue":"2","key":"2019111811515797800_B69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0145-2126(01)00113-8","article-title":"Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.","volume":"26","author":"Tulpule","year":"2002","journal-title":"Leuk Res"},{"issue":"8","key":"2019111811515797800_B70","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.1995.13.8.1995","article-title":"Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.","volume":"13","author":"Wilson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111811515797800_B71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1016168411221","article-title":"Modulation of apoptosis by HIV protease inhibitors.","volume":"7","author":"Phenix","year":"2002","journal-title":"Apoptosis"},{"issue":"4","key":"2019111811515797800_B72","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V98.4.1078","article-title":"Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.","volume":"98","author":"Phenix","year":"2001","journal-title":"Blood"},{"issue":"19","key":"2019111811515797800_B73","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","article-title":"AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.","volume":"23","author":"Lim","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111811515797800_B74","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/07357900009012197","article-title":"Burkitt's lymphoma: molecular pathogenesis and treatment.","volume":"18","author":"Bishop","year":"2000","journal-title":"Cancer Invest"},{"issue":"8","key":"2019111811515797800_B75","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis.","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111811515797800_B76","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia.","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"key":"2019111811515797800_B77","first-page":"3673","article-title":"Feasibility and toxicity of a modified dose intensive R-CODOX-M\/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC) [abstract].","volume":"114","author":"Noy","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"23","key":"2019111811515797800_B78","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1182\/blood-2010-08-301531","article-title":"HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes.","volume":"117","author":"Bohlius","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111811515797800_B79","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/00002030-200111090-00007","article-title":"Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery.","volume":"15","author":"Hoffmann","year":"2001","journal-title":"AIDS"},{"issue":"10","key":"2019111811515797800_B80","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/1097-0142(19940515)73:10<2570::AID-CNCR2820731019>3.0.CO;2-1","article-title":"Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus: ten years of treatment experience at the University of California San Francisco.","volume":"73","author":"Ling","year":"1994","journal-title":"Cancer"},{"issue":"19","key":"2019111811515797800_B81","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","article-title":"Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.","volume":"23","author":"Boulanger","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111811515797800_B82","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajh.10341","article-title":"Combined chemotherapy including high-dose methotrexate in KSHV\/HHV-8-associated primary effusion lymphoma.","volume":"73","author":"Boulanger","year":"2003","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111811515797800_B83","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-08-2525","article-title":"Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B.","volume":"101","author":"Ghosh","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111811515797800_B84","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111811515797800_B85","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1080\/10428190410001697395","article-title":"Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.","volume":"45","author":"Lester","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"34","key":"2019111811515797800_B86","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1200\/JCO.2010.30.0038","article-title":"Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.","volume":"28","author":"Bibas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111811515797800_B87","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.","volume":"114","author":"Re","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111811515797800_B88","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00042560-200112150-00002","article-title":"High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.","volume":"28","author":"Bi","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7277","key":"2019111811515797800_B89","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/14\/3245\/1351325\/zh801412003245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/14\/3245\/1351325\/zh801412003245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T16:58:19Z","timestamp":1574096299000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/14\/3245\/29579\/How-I-treat-HIVassociated-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":89,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,4,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-373738","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]}}}